title: Effect of rosuvastatin on dyslipidemia and other parameters associated with metabolic syndrome in Saudi patients.
abstract: Metabolic syndrome (MS) is a constellation of metabolic irregularities consisting of dyslipidemia, hypertension, hyperglycemia, chronic inflammatory, and hypercoagulable state predisposing to diabetes and cardiovascular events. Statins are first-line drugs to treat the associated atherogenic dyslipidemia.
  
  
  
  Effect of rosuvastatin on MS in Saudi patients was studied.
  
  
  
  Prospective, open label, randomized clinical study.
  
  
  
  Patients of either sex ≥18 years (n = 153) having MS as per modified National Cholesterol Education Program Adult Treatment Panel III criteria were prescribed rosuvastatin 10 mg OD for 24 weeks. Serum lipids, biochemical, clinical, and anthropometric parameters were studied before and after treatment.
  
  
  
  Statistical Package for Social Sciences version17 was used. Descriptive analysis was used for all variables and documented as mean ± SD. Normality checked by Shapiro-Wilk test, Kurtosis and Skewness Z-score, and visualization of histograms. Lipid levels and other parameters before and after treatment were evaluated by paired t-test for parametric data and Wilcoxon signed rank test for nonparametric data. Pre- and post-test values were correlated by Pearson's correlation coefficient. Multiple regression analysis was performed to see effect of other variables.
  
  
  
  Highly significant reduction was observed in low density lipoprotein cholesterol, total cholesterol, triglycerides; very low density lipoprotein cholesterol, non-high density lipoprotein cholesterol and atherosclerotic index with an elevation in high density lipoprotein cholesterol. A total of 86% patients reached low density lipoprotein cholesterol goal of ≤ 100 mg/dL. Beneficial response was observed on other associated parameters. There was strong correlation between pre- and post values. No significant effect was observed for any of the variables on cholesterol reduction. No serious/severe adverse effect was observed.
  
  
  
  Rosuvastatin markedly improved atherogenic dyslipidemia of MS.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, Rabigh Campus, King Abdulaziz University, Jeddah, Saudi Arabia.
authors.forename: M M
authors.initials: MM
authors.lastname: Rafeeq
authors.affiliation: Department of Paediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
authors.forename: H S
authors.initials: HS
authors.lastname: Habib
authors.affiliation: Department of Pharmacology, Faculty of Medicine, Ainshams University, Cairo, Egypt.
authors.forename: Has
authors.initials: H
authors.lastname: Murad
authors.affiliation: Department of Laboratory Medicine, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
authors.forename: M A
authors.initials: MA
authors.lastname: Gari
authors.affiliation: Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
authors.forename: Z J
authors.initials: ZJ
authors.lastname: Gazzaz
mesh_terms: D008076:Cholesterol, HDL / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood*; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D008875:Middle Aged; D009017:Morbidity / Q000639:trends; D011446:Prospective Studies; D000068718:Rosuvastatin Calcium / Q000627:therapeutic use*; D012529:Saudi Arabia / Q000453:epidemiology; D014280:Triglycerides / Q000097:blood*
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014280:Triglycerides; D000068718:Rosuvastatin Calcium